Simone Belmonti
Rome, 00168, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
Factors associated with oxidative stress in virologically suppressed people living with HIV on long-term antiretroviral therapy.
Journal: AIDS research and therapy
Published: August 28, 2024
Response to BNT162b2 mRNA COVID-19 vaccine of ART-experienced people living with HIV: a prospective analysis from a single-center study in Rome, Italy.
Journal: Le infezioni in medicina
Published: June 29, 2023
Inflammation markers in virologically suppressed HIV-Infected patients after switching to dolutegravir plus lamivudine vs continuing triple therapy: 48-week results in real-life setting.
Journal: HIV research & clinical practice
Published: June 27, 2022
Quantification of Total HIV DNA as a Marker to Measure Viral Reservoir: Methods and Potential Implications for Clinical Practice.
Journal: Diagnostics (Basel, Switzerland)
Published: September 20, 2021
External quality assessment of HIV-1 DNA quantification assays used in the clinical setting in Italy.
Journal: Scientific reports
Published: August 26, 2021
Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Rome, Italy during the COVID-19 Outbreak.
Journal: Diagnostics (Basel, Switzerland)
Published: May 26, 2021
Risk of Tumor Onset in HIV+ Patients on Two-Drug Regimens: A Cohort Study in an Italian Hospital.
Journal: AIDS research and human retroviruses
Published: December 16, 2020
No evidence of SARS-CoV-2 circulation in HIV-infected patients between December 2019 and February 2020 in Rome, Italy.
Journal: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
Published: October 08, 2020
Comparison of HIV-DNA decay in naive patients starting dolutegravir plus lamivudine or dolutegravir-based triple therapy.
Journal: Le infezioni in medicina
Published: September 13, 2020
Evolution of cellular HIV DNA levels in virologically suppressed patients switching to dolutegravir/lamivudine versus maintaining a triple regimen: a prospective, longitudinal, matched, controlled study.
Journal: The Journal of antimicrobial chemotherapy
Published: December 05, 2019
Reduced soluble CD14 levels after switching from a dual regimen with lamivudine plus boosted protease inhibitors to lamivudine plus dolutegravir in virologically suppressed HIV-infected patients.
Journal: HIV research & clinical practice
Published: September 04, 2019
Last Updated: 09/26/2026